Avidity Partners Management LP

CIK 0001791827 · DALLAS, TX · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source

Avidity Partners Management LP reported 45 positions worth $624.4M as of June 30, 2026 (13F filed August 14, 2026). Largest holding: DNTH (32.8%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$624.4M
2026 Q2
Positions
45
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
81.9%
Est. Net Flow (Q)
2026 Q2
10 / 45 positions shown
#SymbolCompanyTypeValue% Port.Shares1YYTD
1DNTHDIANTHUS THERAPEUTICS INCSH$205.1M32.85%2,104,184
2CGONCG ONCOLOGY INCSH$99.4M15.92%1,398,948
3ORKAORUKA THERAPEUTICS INCSH$72.4M11.59%760,424
4JBIOJADE BIOSCIENCES INCSH$37.8M6.05%1,700,708
5ELVNENLIVEN THERAPEUTICS INCSH$27.9M4.47%550,000
6CATXPERSPECTIVE THERAPEUTICS INCSH$21.5M3.44%6,299,999
7AKTSAKTIS ONCOLOGY INCSH$15.6M2.50%484,200
8PVLAPALVELLA THERAPEUTICS INC NESH$10.7M1.71%70,000
9MOBIMOBIA MED INCSH$10.7M1.71%798,282
10RGENREPLIGEN CORPSH$10.6M1.70%77,800

The free plan shows the top 10 positions. The remaining 35 positions, the full portfolio and quarter changes unlock with Pro.

Pro Feature

This section is exclusive to Fundocap Pro. Full holdings tables, consensus trades, ownership analysis, backtests and exports unlock with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Avidity Partners Management LP hold as of Q2 2026?

Avidity Partners Management LP reported 45 positions worth $624.4M in its Q2 2026 13F filing. Largest positions: DNTH (32.8%), CGON (15.9%), ORKA (11.6%), JBIO (6.1%) and ELVN (4.5%).

What did Avidity Partners Management LP buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Avidity Partners Management LP sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.